Pfizer says IRA impact will be 'modest,' maps out R&D priority changes

Nicole DeFeudis

Editor

Despite being an early critic of the Inflation Reduction Act, Pfizer told investors on Monday that the legislation is likely to have a “modest” impact …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer says IRA impact will be 'modest,' maps out R&D priority changes

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Sage sues Biogen days after $469M buyout offer

Another US biotech emerges with drug candidate from China-based Keymed

Sionna and Odyssey end JPM week with IPO filings

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Ozempic makes list for next round of Medicare drug price negotiations

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

Pfiz­er says IRA im­pact will be 'mod­est,' maps out R&D pri­or­i­ty changes

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pfizer says IRA impact will be 'modest,' maps out R&D priority changes